DURHAM, NC – Polaris Quantum Biotech has been selected as a 2026 winner of the Cleveland Clinic Quantum Innovation Catalyzer Program!
We’re working to transform drug discovery by combining advanced computing with personalized medicine. Our focus? Improving one of the biggest bottlenecks in drug development by using quantum machine learning to significantly enhance AI models for predicting Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME-Tox) properties.
Through this program, we’ll collaborate with Cleveland Clinic researchers and leverage IBM Quantum System One to advance quantum machine learning approaches that enhance toxicity prediction.
For more information:
Polaris Quantum Biotech (PolarisQB) is working to revolutionize drug design through advanced computing and personalized medicine. The company, based in North Carolina, built the first drug-discovery platform using quantum computers. Additional information is available at www.polarisqb.com.
